This is not a new demonstration format. It follows our existing public-case verification process. The source is an official public DeciBio case. We isolated the later-published answer first, then reconstructed only what was knowable at the moment of decision into a teaching data pack. This is an independent teaching simulation based on that public source, not real correspondence, and not real client results. It does not imply that DeciBio used, reviewed, endorsed, sponsored, certified, or commissioned Minerva Advisor.

The case opens with a research tools and diagnostics company generating roughly one hundred million dollars in revenue, weighing whether to push forward on a novel multi-omic technology. Priority applications, adoption willingness, specifications, volume, and pricing were all still unvalidated. Minerva Advisor was asked to compare three paths: commit immediately to full development, pause entirely, or set a time-bound, stoppable evidence threshold before scaling.

The session left a five-item work receipt. Minerva identified the roles involved in the decision, separated established facts from inference, flagged open questions still requiring evidence, mapped the two primary paths under consideration, and preserved alternative explanations alongside a stated reversal condition. Every item is auditable, so the reasoning trail can be checked step by step rather than taken on faith.

What was known: the company needed to identify priority applications and revenue potential before committing further. What remained unknown: which applications would be prioritized, whether users would actually adopt and pay, what specifications the deliverable required, and what volume and pricing assumptions could hold. Minerva was explicit that market enthusiasm cannot be treated as equivalent to achievable revenue.

The strongest challenge raised was that a stoppable validation approach assumes waiting to validate first won't cost the company its competitive window. If rival technologies advance quickly during that pause, the assumption breaks down. The reversal condition follows directly: if evidence emerges showing that competitor timing or a closing window makes delay itself irreversible, the recommendation escalates to immediate full development, even with demand still unvalidated.

Held out from the input entirely was DeciBio's later-published answer: a review of roughly three hundred fifty publications and clinical trials, thirty interviews with key opinion leaders and industry experts, more than one thousand data inputs, modeled service and platform scenarios, the client's eventual decision to proceed with development, and early experience programs confirming that commitment. None of that was available to Minerva during the run, so the judgment had to stand on its own.

Three advisors cross-checked one judgment. One advisor narrowed the question to exactly what evidence would justify a go, pause, or no-go call. A second modeled second-order consequences across product, commercial, development, and the investment committee. A third challenged whether the proposed evidence gate underestimated how quickly the competitive window might close. All three converged on the same direction: small-scale, stoppable validation first, with a defined path to escalate.

The executive weighed in directly, instructing that the evidence gate must explicitly cover paying adoption, deliverable specifications, pricing, and the length of the competitive window, and that limited development should be allowed if window evidence ever outweighed the risk of irreversible cost. Minerva recorded this as a response receipt, preserving the validate-first direction while sharpening the reversal condition around window timing.

The system then let the executive see whether that input actually changed the underlying judgment. Immediate full development might capture the window, but with applications and pricing unvalidated, it risks high irreversible cost. A full pause preserves resources but may forfeit the opportunity outright. A time-bound validation of applications and adoption preserves the option to escalate or stop, at the cost of time. The executive's added condition tightened the middle path rather than replacing it.

The executive chose that middle path. The commercial evidence and product teams were assigned to complete minimal, time-boxed tests of candidate applications, adoption willingness, specifications, and pricing, then report back to the investment committee with go, pause, or no-go evidence in hand. Minerva Advisor does not constitute medical, diagnostic, investment, or research and development advice.

On this actual English-language run, the case passed all ten decision-quality checks. Minerva used four model calls, delivered its first decision in 17.003 seconds, and completed the full result in 22.926 seconds, clearing both the 30-second first-decision threshold and the 45-second complete-result threshold. This remains a single-case test and does not represent production service levels or real customer outcomes.